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ABSTRACT
X-linked adrenal hypoplasia congenita (AHC) is a disorder asso-
ciated with primary adrenal insufficiency and hypogonadotropic hy-
pogonadism (HH). The gene responsible for X-linked AHC, DAX1,
encodes a member of the nuclear hormone receptor superfamily. We
studied an extended kindred with AHC and HH in which two males
(the proband and his nephew) were affected with a nucleotide deletion
(501delA). The proband’s mother, sister, and niece were heterozygous
for this frameshift mutation. At age 27 yr, after 7 yr of low dose hCG
therapy, the proband underwent a testicular biopsy revealing rare
spermatogonia and Leydig cell hyperplasia. Despite steadily progres-
sive doses of hCG and Pergonal administered over a 3-yr period, the
proband remained azoospermic. The proband’s mother, sister (obli-
gate carrier), and niece all had a history of delayed puberty, with
menarche occurring at ages 17–18 yr.
Baseline patterns of pulsatile gonadotropin secretion and gonad-
otropin responsiveness to exogenous pulsatile GnRH were examined
in the affected males. LH, FSH, and free a-subunit were determined
during 12.5–24 h of frequent blood sampling (every 10 min). Both
patients then received pulsatile GnRH (25 ng/kg) sc every 2 h for 6–7
days. Gonadotropin responses to a single GnRH pulse iv were mon-
itored daily to assess the pituitary responsiveness to exogenous
GnRH. In the proband, FSH and LH levels demonstrated a subtle, but
significant, response to GnRH over the week of pulsatile GnRH ther-
apy. Free a-subunit levels demonstrated an erratic pattern of secre-
tion at baseline and no significant response to pulsatile GnRH.
We conclude that 1) affected males with AHC/HH may have an
intrinsic defect in spermatogenesis that is not responsive to gonad-
otropin therapy; 2) female carriers of DAX1 mutations may express
the phenotype of delayed puberty; and 3) although affected individ-
uals display minimal responses to pulsatile GnRH, as observed in
other AHC kindreds, subtle differences in gonadotropin patterns may
nevertheless exist between affected individuals within a kindred.
(J Clin Endocrinol Metab 84: 4501–4509, 1999)
ADRENAL hypoplasia congenita is a rare developmen-tal disorder of the adrenal gland. In the X-linked cy-
tomegalic form, the adrenal glands lack the permanent adult
zone of the adrenal cortex (1). Affected boys typically present
with adrenal insufficiency in early infancy or childhood and
hypogonadotropic hypogonadism (HH) at the time of
puberty (2). The gene responsible for adrenal hypoplasia
congenita (AHC) is DAX1 (dosage-sensitive, sex reversal,
adrenal hypoplasia congenita, critical region on the X-chro-
mosome, gene 1), which encodes for a protein that is a mem-
ber of the orphan nuclear hormone receptor superfamily (3,
4). Although the carboxyl-terminus of DAX-1 (putative li-
gand-binding domain) displays sequence homology with
several other transcription factors, the amino-terminus of
DAX-1 has a novel amino acid tandem repeat structure that
lacks the zinc finger motif typically present in the DNA-
binding domain of other nuclear hormone receptors (4). A
range of frameshift and nonsense mutations has been re-
ported throughout DAX1 in patients with AHC and HH.
These mutations cause truncation of the functionally impor-
tant carboxyl-terminal region of the protein (5). Missense
mutations in DAX1 are relatively rare and, to date, are also
localized within the putative ligand-binding domain alone
(5). Additional lines of evidence suggest that such disrup-
tions of the C-terminus impair DAX-1 interaction with ste-
roidogenic factor-1 (6).
Long term data on gonadal function in patients with
AHC/HH is lacking. No cases of true fertility have yet been
reported in men with this condition. It is unclear whether
fertility can be induced in these patients by using exogenous
gonadotropins, as Dax-1 is also expressed in Sertoli cells, and
the recently reported Ahch (Dax1) knockout mouse demon-
strates markedly disordered spermatogenesis (7). In addi-
tion, little information has been available regarding the phe-
notypic status of female carriers of DAX1 gene mutations.
However, recently, a female with isolated HH was found to
be homozygous for a DAX1 nonsense mutation, demonstrat-
ing a unique molecular etiology for this disorder (8).
Much of the early clinical data on AHC patients examined
whether the hypogonadism of these individuals was due to
defects at the hypothalamus or pituitary. Attempts to stim-
ulate gonadotropin secretion were conducted using pulsatile
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GnRH. Although these cases predated the discovery of
DAX1 (and, by extension, do not represent confirmed DAX1
mutations), investigators were unable to resolve whether the
hypogonadism of AHC was of hypothalamic or pituitary
origin (9–13). However, by 1) conducting frequent (every
10–20 min) blood sampling for LH, FSH, and free a-subunit
(FAS) to examine the baseline pulsatile activity of the hypo-
thalamic-pituitary-gonadal (HPG) axis and 2) administering
exogenous pulsatile GnRH at physiological doses to two
patients with different DAX-1 mutations, we have been able
to demonstrate that DAX-1 can impair gonadotropin pro-
duction by acting at both hypothalamic and pituitary levels
(14).
This study presents an extended kindred with AHC/HH.
The proband of this family failed to develop spermatogenesis
despite 3 yr of exogenous gonadotropin therapy, suggesting
the presence of an independent gonadal defect in AHC/HH.
In addition, this family demonstrates the novel finding that
delayed puberty can be a manifestation of DAX1 mutations
in females. The results of detailed hypothalamic-pituitary-
gonadal investigations in two members of this kindred are
also presented.
Subjects and Methods
Case presentations
The proband, III-9 (Fig. 1), was the product of a full-term, normal,
spontaneous delivery. He presented at 11 days of life with poor intake,
drowsiness, and weight loss and presented again at 4 weeks with mal-
nutrition and dehydration. At that time, examination revealed mottled
skin with poor turgor, but the abdomen, genitalia, and extremities were
normal. Electrolyte determinations consistently showed low sodium
and chloride and elevated potassium levels. Serum cortisol levels were
subnormal, with only a 2- to 3-fold increase after ACTH administration.
The patient remained hospitalized for the next 2.5 months and received
cortisone treatment. He was discharged with a diagnosis of transient
hypoadrenalism of infancy. Although he did not require any steroid
supplementation during childhood, III-9 recollects a childhood prefer-
ence for salty foods. He presented at age 12 yr with anorexia, weight loss,
poor growth, and hyponatremia (Na, 118 mEq/L). Physical examination
was notable for hyperpigmentation, and he was begun on hydrocorti-
sone and fludrocortisone treatment.
In his teen years, III-9 presented with delayed puberty. A presump-
tive diagnosis of HH was made, and hCG (1000 U, im, every 5 days) was
initiated at age 19 yr. An excellent response to hCG was evident, with
respect to both virilization and sexual function. He was 5 ft 4 in. when
he graduated high school and 6 ft 4 in. when he graduated college. At
age 27 yr, a testicular biopsy was performed, which revealed Sertoli cell
only syndrome with rare spermatogonia and no apparent spermato-
genesis (Fig. 2).
After the biopsy, in an attempt to achieve fertility, III-9 initiated
combination therapy with hCG and Pergonal (75 U, im, three times per
week). Initially, physical examination revealed a testicular size of 5 cc
bilaterally. After 3 yr of therapy (dose escalations to 2000 U hCG and 150
U Pergonal, im, three times per week), testicular size increased to 10 cc
bilaterally, but semen analyses failed to show any sperm. The patient
discontinued gonadotropins, declined pulsatile GnRH, and initiated
testosterone therapy.
The patient had five siblings, three of whom died prematurely. A 14-
yr-old sister had homocystinuria (III-8), a 2.5-yr-old sister died of nephritis
(III-3), and a boy born 2 months prematurely died at 2.5 days of age (III-2).
The proband’s brother underwent normal puberty and development. The
proband’s father had a history of thyrotoxicosis. His mother (II-4) had a
history of delayed puberty, with menarche at age 17 yr.
The patient III-9’s surviving sister (III-4), similar to her mother, also
underwent a delayed menarche at age 17–18 yr. However, after com-
pletion of puberty, she maintained regular menstrual cycles and con-
ceived two children. In 1981, she had a healthy daughter (IV-1), who had
normal growth and development, but did not undergo menarche until
age 17 yr. Although the history is vague, both III-4 and IV-1 underwent
pubarche and thelarche in their early teens. All three women in this
lineage had no history of eating disorder, marked weight loss, major life
stressors, or competitive athletics, with the exception of IV-1, who ran
on her high school track team.
In 1983, III-4 bore a son (IV-2) who was an 8-lb 5-oz product of an
uncomplicated full-term pregnancy. He presented at 4 weeks of age with
irritability, dehydration, hyponatremia, and hyperkalemia. Physical ex-
amination revealed a slightly thin but well developed male infant with
normally descended testes. During hospital admission, IV-2 was treated
with hydrocortisone and iv sodium chloride; fludrocortisone and de-
oxycorticosterone acetate were added to his regimen. Work-up revealed
an elevated serum renin, low serum aldosterone, and normal serum
testosterone (209 ng/dL), LH (6 mIU/mL), FSH (2 mIU/mL), and 17a-
hydroxyprogesterone (352 ng/dL). Patient IV-2 was switched to dexa-
methasone and readmitted at 7.5 weeks for confirmation of his diagnosis
with ACTH stimulation testing. A 3-day ACTH stimulation test yielded
no cortisol elevation, and he was restarted on hydrocortisone and fludro-
cortisone, with intermittent injections of deoxycorticosterone.
Patient IV-2 remained well below the fifth percentile on his growth
curve throughout infancy and childhood, with a height age equivalent
to 4 yr at age 6 yr. He had two episodes of adrenal insufficiency,
FIG. 1. Family pedigree.
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presenting primarily with hypoglycemia, once at 15 months during
gastroenteritis and otitis media, and once at 7 yr, with gastroenteritis,
vomiting, and fever. At 9 2/12 yr, IV-2 underwent dynamic anterior
pituitary testing. In response to 0.10 U/kg insulin, his GH level rose from
14 to 33 ng/mL (normal, .10). His cortisol level showed no response,
with a baseline level of 11 mg/dL that failed to increase during testing.
In response to 400 mg TRH, his TSH levels rose from a baseline of 1.3
mIU/mL to a peak TSH of 5.0 mIU/mL, an inadequate response (normal,
increase of 10–30). His PRL rose from a baseline of 6 ng/mL to a peak
level of 52 ng/mL (normal, .20 or 3 times baseline). In response to 100
mg GnRH, LH remained less than 0.5 mIU/mL and FSH less than 1.0
mIU/mL at all time points. At a chronological age of 9 2/12 yr, IV-2’s
bone age was 6 yr.
At 12 3/12 yr, patient IV-2 continued to be well below the fifth
percentile on the normal growth curves (height, 51 in.; height age, 8 6/12
yr; predicted height using Bayley prediction tables, 68 in.). Physical
examination revealed no pubic or axillary hair and prepubertal testes.
Bone age remained markedly delayed at 6 6/12 to 8 yr. On repeat GnRH
stimulation testing, testosterone levels at 1 and 120 min were less than
3 ng/100 mg. FSH levels rose from 2.4 mIU/mL to a peak of 4.6 mIU/mL
at 120 min. LH levels rose from 0.16 mIU/mL to a peak of 1.1 mIU/mL
at 60 min.
Clinical studies
After obtaining written informed consent, both patients were admit-
ted to the General Clinical Research Center at the Massachusetts General
Hospital, patient III-9 in 1980 (age 22 yr) and patient IV-2 in 1998 (age
15 yr). Patient III-9 discontinued his hCG for 8 weeks before the study,
and patient IV-2 was not taking any hormone replacement therapy.
Frequent blood sampling every 10–20 min was performed for 12.5–24 h
for measurement of LH, FSH, and FAS. FSH levels were measured from
hourly pools, and testosterone levels were measured from 6-h pools of
serum. After completion of frequent sampling, each patient received
pulsatile GnRH (25 ng/kg) sc via pulsatile pump every 2 h for 6–7 days.
Each morning while using the GnRH pump, gonadotropin responses to
a single iv GnRH bolus were monitored. LH, FSH, and FAS levels were
determined every 15 min for 2 h after the GnRH pulse.
Assays
Serum LH and FSH concentrations were determined by immunoas-
says calibrated against the Second International Reference Preparation
of human menopausal gonadotropin (hMG; WHO 71/223) (15–17). For
patient III-9, the minimum detectable dose was 0.8 mIU hMG (WHO
71/223)/mL; for patient IV-2, the minimum detectable dose was 1.6 mIU
hMG (WHO 71/223)/mL. Inter- and intraassay coefficients of variation
were less than 10%. FAS was measured using a monoclonal antibody
RIA, with a highly purified a-subunit of hCG as the standard (18, 19).
Testosterone levels were also measured by RIA (20). Secretory patterns
were analyzed for pulses using a modified version of the Santen and
Bardin method (21). Statistical analysis was performed using a New-
man-Keuls ANOVA.
Direct sequencing of DAX1
After obtaining informed consent, blood samples were taken from
individuals II-4, III-4, III-9, IV-1, and IV-2, and leukocyte DNA was
extracted. Exons 1 and 2 of DAX1 were amplified by PCR using primers
and conditions described previously (5). Direct sequencing of PCR prod-
ucts was performed using the dRhodamine terminator cycle sequencing
kit (Perkin-Elmer Corp., Palo Alto, CA) and automated sequencer (mod-
el 377, PE Applied Biosystems, Foster City, CA). After detection of a
mutation, additional primers were used to PCR amplify the region of
interest (forward, 59-GCTCAAAGCAAACGCACGTGGCTC-39; re-
verse, 59-GACGAAGCGCAGCGTCTTCAACAG-39). Restriction en-
zyme analysis of this DNA fragment was performed using MspI (Pro-
mega Corp., Madison, WI).
Results
Mutation analysis of the DAX1 gene
Direct sequencing of DAX1 revealed a hemizygous
501delA mutation in both the proband (III-9) and his affected
nephew [IV-2; Fig. 3A; A of the ATG start codon designated
11; 501delA of IV-2 previously reported (22)]. This single
nucleotide deletion results in a frame shift and premature
stop codon at position 263. Three women (II-4, III-4, and IV-1)
from different generations of this kindred, each with mark-
edly delayed puberty, were all heterozygous for this 501delA
mutation (Fig. 3A). Deletion of this nucleotide creates a novel
MspI restriction site. Restriction enzyme analysis confirmed
the hemizygous status of affected males and the heterozy-
gous carrier status of females (Fig. 3B).
Baseline gonadotropin secretion
Patient III-9 (Fig. 4A) exhibited apulsatile gonadotropin
secretion, with LH levels below the limits of detection of the
FIG. 2. Photomicrographs (A, 3200; B, 3 400) of the testicular biopsy
of the proband, III-9, after 5 yr of low dose hCG therapy. A, Sertoli cell
only syndrome with no germ cells demonstrable within the seminif-
erous tubules. LC, Leydig cell hyperplasia. B, Higher magnification
of single seminiferous tubule. The arrow demarcates one of the rare
spermatogonia identified in the specimen.
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assay (,0.8 mIU/mL). FSH levels were at the low end of the
normal male range (mean FSH, 1.2 mIU/mL), but FAS levels
were well within the normal range (mean FAS, 126.2 pg/
mL). Six FAS pulses were detected by modified Santen and
Bardin analysis. In patient IV-2 (Fig. 4B), LH levels were
below the limits of detection (,1.6 mIU/mL) for every data
point in the study. Mean FSH and FAS levels equaled 3.5
mIU/mL and 34.9 pg/mL, respectively. No FAS pulses were
detectable.
Response to pulsatile GnRH
Both III-9 and IV-2 received pulsatile GnRH for 7 and 6
days, respectively, to examine their pituitary responsive-
ness to exogenous pulsatile GnRH (Fig. 5). There was no
initial gonadotropin pulse for either patient on day 1 of
therapy. For patient III-9, FSH levels tripled from day 1 to
day 7 of GnRH therapy (P , 0.001; Fig. 5A). LH levels
remained at the level of assay sensitivity for the first 4 days
of the study, then increased significantly over the course
of the last 3 days (P , 0.005). Testosterone levels increased
from 6 to 141 ng/dL during the week. FAS levels did not
change significantly.
Patient IV-2 demonstrated no change in LH, FAS, or tes-
tosterone levels over the course of 6 days of GnRH therapy
(Fig. 5B). However, mean FSH levels increased modestly, but
significantly, from day 1 to day 6 (P , 0.001).
Discussion
This study examines genotype/phenotype correlations in
both the male and female members of an extended kindred
with congenital adrenal hypoplasia. Despite extensive ther-
apy with exogenous gonadotropins, the proband of this kin-
dred, III-9, was not able to achieve fertility. The family his-
tory coupled with the mutation analysis strongly suggest
that delayed puberty may be a manifestation of X-linked
DAX1 gene defects in female heterozygotes. Both the pro-
band and his nephew demonstrated minimal responses to
exogenous pulsatile GnRH. However, the proband demon-
strated an erratic pattern of FAS secretion at baseline, as has
been previously documented in patients with AHC/HH (14),
whereas his nephew had no evidence of endogenous go-
nadotropin secretion. These observations raise a number of
new issues about AHC, including 1) the variety of pheno-
types included within the diagnosis, and 2) the spectrum of
presentations within a family.
In the rat, Dax-1 is expressed in Sertoli cells, with maximal
levels present during the first spermatogenic wave (postnatal
days 20 and 30) (23). However, Dax-1 expression declines to
low basal levels in the 40-day-old, sexually mature animal,
demonstrating a pattern of developmental regulation. The
mouse model of AHC, created by targeted disruption of the
mouse homolog of DAX1 (Ahch), has extended our under-
standing of the role of this gene mutant in gonadal function
FIG. 3. Left, Direct DNA sequencing revealed a hemizygous 501delA mutation in affected males (III-9 and IV-2). Females (II-4, III-4, and IV-1)
appeared heterozygous for this mutation. Right, Deletion of this nucleotide creates a novel MspI restriction site (C/CGG) in the sequence. Carrier
status could therefore be confirmed by restriction analysis.
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FIG. 4. Baseline secretory pattern of LH and FAS in III-9 (A) and IV-2 (B). Each graph depicts the results of gonadotropin determinations made
at 10- to 20-min intervals. Patient III-9 was studied for 24 h; patient IV-2 was studied for 12.5 h. The shaded area for LH and FSH represents
the mean 6 2 SD for each hormone as determined in 20 normal men.
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FIG. 5. Gonadotropin responses to 6–7 days of pulsatile GnRH in III-9 (A) and IV-2 (B). Each patient received pulsatile GnRH (25 ng/kg, iv,
every 2 h). A single GnRH pulse was monitored each morning. Testosterone levels are indicated at the top of each panel. Note the change in
axes compared with Fig. 4. Refer to Fig. 4 for normative ranges.
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(7). Based on observations in the human, it was originally
hypothesized that the hypogonadism of AHC in mice would
be due to deficient gonadotropin secretion. However, mutant
mice had normal levels of LH and FSH; pituitary immuno-
histochemical staining for LHb and FSHb was also normal.
Male mice demonstrated a primary testicular defect with
progressive seminiferous tubule epithelial degeneration,
leading to a complete loss of germ cells by 14 weeks. Leydig
cell hyperplasia was also observed, suggesting either an in-
dependent Leydig cell defect due to Ahch disruption or a
secondary response to the Sertoli cell defect.
Although the differences between human and mouse phe-
notypes could be explained by species-specific pathways,
there is a paucity of data regarding testicular histology and
induction of spermatogenesis in men with AHC. Schwartz et
al. reported the case of an affected male who underwent a
short course of pulsatile GnRH and produced a semen sam-
ple with a few spermatozoa (24). However, further details
regarding sperm count, morphology, and motility were not
described. In the present report, the proband underwent a
testicular biopsy after 7 yr of low dose hCG therapy, reveal-
ing essentially Sertoli cell only syndrome with Leydig cell
hyperplasia. However, 3 yr of escalating doses of both hCG
and Pergonal failed to induce spermatogenesis despite an
increase in testicular size from 5 to 10 cc. These findings
suggest that even when bypassing the hypothalamic-pitu-
itary axis with exogenous gonadotropins, AHC patients can
harbor an intrinsic gonadal defect. The degeneration of large
segments of the seminiferous tubules observed in knockout
mice suggests that Ahch is necessary for maintenance of
epithelial integrity and spermatogenesis. Extending this con-
cept to the human male, restoration of a normal hormonal
milieu in AHC/HH appears unable to overcome this defect.
The age of onset of AHC appears to be variable. Most
patients present with salt wasting in neonatal life, but a
significant fraction are well into their childhood years before
presentation (5). Although the hypogonadotropic hypogo-
nadism associated with AHC is conventionally perceived as
a congenital disorder, recent data have demonstrated tran-
sient postnatal activation of the HPG axis in AHC patients.
Normal serum gonadotropin and testosterone levels have
been demonstrated in a newborn male with AHC and a
confirmed DAX1 mutation (A300V) (25). Hormonal data
from four boys with AHC (aged 1–3 months) have also sug-
gested an active HPG axis (26). In the current report, the
proband’s nephew demonstrated a neonatal testosterone
level of 209 ng/dL in the setting of a LH level of 6 mIU/mL
during this same developmental window. These findings
suggest that the mechanisms that control neonatal activation
of the HPG axis may be distinct from those occurring at
puberty or that the hypogonadotropic hypogonadism of
AHC worsens over time. Therefore, our understanding of the
hypogonadotropic hypogonadism associated with AHC
continues to evolve, encompassing defects at the hypothal-
amus, pituitary, and perhaps even gonad, with congenital
and developmental components.
Despite these insights into the age spectrum of AHC in
male patients, until recently, little information has been avail-
able regarding the adrenal or pubertal phenotype in female
carriers of DAX1 gene mutations. Merke et al. reported two
boys with AHC/HH and a nonsense mutation in the DNA-
binding domain of the DAX1 gene (8). The boys’ maternal
aunt, who was homozygous for the nonsense mutation
through gene conversion, had the phenotype of isolated hy-
pogonadotropic hypogonadism, demonstrating a surprising
range of phenotypes in this one family. In the kindred re-
ported here, three female heterozygotes carrying the del501A
mutation all underwent markedly delayed menarche. De-
layed puberty in female carriers may thus represent a forme
fruste of the hypogonadotropic hypogonadism associated
with AHC. Although it is possible that there are other eti-
ologies for the delayed puberty in these women, no com-
monly implicated physiological or genetic factors could be
elicited by history. Although the women in this kindred may
have had an incomplete form of central hypogonadism, there
is no evidence to suggest that any of them had adrenal
dysfunction. The possibility that these women might have
had abnormal DHEAS or aldosterone levels or diminished
adrenal reserve on formal ACTH testing could not be
studied.
Partial expression of X-linked disorders in heterozygous
females has been well documented for a number of condi-
tions, including ornithine transcarbamylase deficiency (27,
28), Duchenne muscular dystrophy (29, 30), and fragile X
mental retardation (31). Although it is assumed that female
somatic cells undergo a 50:50 random X inactivation, this is
often not true in a given individual or clonal cell population.
Therefore, if a female carrier has a higher proportion of
mutant alleles on the active X-chromosome in a relevant cell
lineage (i.e. skewing), she may show symptoms similar to
those of a hemizygous affected male, as has been observed
in hemophilia B (32). Although in the current report, multiple
females within a single kindred had delayed menarche, fa-
milial nonrandom X inactivation has been described in some
rare pedigrees [Duchenne muscular dystrophy (30) and he-
mophilia B (33)]. Although no direct evidence is presented in
the current study to support familial skewing, the possibility
of genetic determinants in the randomness of X inactivation
remains an important model to consider (34, 35). In addition
to extended pedigrees, further studies will be needed to
determine whether DAX1 mutations occur in females with
delayed puberty who do not have a family history of
AHC/HH.
Long term data on hypothalamic-pituitary-gonadal func-
tion in patients with AHC/HH are also lacking. Age at di-
agnosis has been used to assess the severity of AHC (5), but
no standardized biochemical testing yet appears available as
a marker of reproductive phenotype. Using pulsatile GnRH
therapy, investigators have observed patterns consistent
with both hypothalamic and pituitary defects (9–14). In the
current study, both the proband and his nephew shared
many similarities with respect to their gonadotropin profiles.
Neither individual demonstrated LH pulsatility at baseline.
During a 1-week exposure to exogenous pulsatile GnRH,
both patients demonstrated significant elevations of FSH
compared to baseline levels, but the responses were very
modest compared to those in patients with Kallmann syn-
drome, a type of HH due to an isolated hypothalamic defect
in GnRH secretion. Our group has shown that Kallmann’s
patients given an identical regimen of pulsatile GnRH dem-
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onstrate a more robust gonadotropin response, with marked
increases in both LH and FSH secretion occurring within 1
week (14).
Despite these gross similarities, there were also some im-
portant differences in the gonadotropin profiles between the
affected males of this kindred. Although IV-2 had flat FAS
levels, III-9 had FAS levels well within the normal male range
with evidence of erratic pulsatility, suggesting GnRH-inde-
pendent stimulation to the gonadotrope. Patient III-9 also
had significant elevations of both LH and FSH over the week
of GnRH exposure, whereas IV-2 demonstrated a significant
change in only FSH. Patient III-9’s rise in LH, although quite
subtle, was accompanied by a marked rise in his testosterone
level from 6 ng/dL (day 1) to 141 ng/dL (day 7). Prior
therapy with hCG may have allowed III-9 to achieve a greater
mass of Leydig cells and hence an increase in testosterone
compared to his nephew, although both received identical
pulsatile GnRH regimens and had similarly meager LH re-
sponses. Nonetheless, one might have expected a somewhat
more dramatic rise in LH to have accompanied the elevation
in testosterone, raising the possibility that FSH itself may
induce Leydig cell steroidogenesis or that it stimulates an-
other factor to induce testosterone production. Although
recombinant FSH does not appear to have a direct effect on
testosterone production in vitro, recent data suggest that FSH
may increase the production of a Sertoli cell-secreted factor
able to up-regulate testicular steroidogenesis (36). Therefore,
although both patients demonstrated atypical responses to
GnRH compared to other states of GnRH deficiency, subtle
differences between these two patients suggest that the pro-
band has a less severe reproductive phenotype than his
nephew.
In addition, the proband of this family survived 12 yr
without glucocorticoid or mineralocorticoid replacement,
suggesting that he also has a less severe form of adrenal
insufficiency. Intrafamilial variability in the temporal ex-
pression and degree of adrenal insufficiency has been re-
ported by a number of investigators (5). In a kindred pre-
viously reported by our group, the presentation of adrenal
insufficiency spanned 1 day to 8 yr among affected individ-
uals (14). The proband’s nephew never had steroid therapy
withdrawn after neonatal life, so it is not known whether he
could have survived off of therapy. In the future, serial mon-
itoring of ACTH levels in male patients with known DAX1-
inactivating mutations may help investigators to more pre-
cisely determine the onset of adrenal insufficiency. Although
most AHC patients are found to have HH when they reach
pubertal age, not all patients have been found to have mu-
tations in the DAX1 gene, suggesting that other gene defects
or epigenetic phenomena may lead to the same phenotype
(3).
In summary, this study adds to the growing body of in-
formation of the hypogonadism of AHC and expands the
phenotype of this disorder to include intrinsic defects in
spermatogenesis in men and possibly delayed puberty in
women. Both members of this kindred demonstrated go-
nadotropin profiles consistent with a pituitary defect, but
subtle differences between the profiles suggest that the re-
productive phenotype was less severe in the proband.
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